Recombinant monoclonal antibody to CD37. Lilotomab is a mouse monoclonal antibody that can be potentially used in the treatment of Non-Hodgkin's lymphoma (NHL).
Figure 1 Toxicity of Lilotomab.
Lack of correlation between RM dose derived by surrogate method and reduction in thrombocyte (A) and neutrophil (B) counts demonstrates that this non–imaging-based method is unfit to predict marrow toxicity for 177Lu-lilotomab satetraxetan therapy.
Blakkisrud, J., Løndalen, A., Dahle, J., Turner, S., Holte, H., Kolstad, A., & Stokke, C. (2017). Red marrow–absorbed dose for non-hodgkin lymphoma patients treated with 177lu-lilotomab satetraxetan, a novel anti-cd37 antibody–radionuclide conjugate. Journal of Nuclear Medicine, 58(1), 55-61.
Figure 2 DNA content and DNA damage in U-2932 and RIVA cells after treatment with 177Lu-lilotomab satetraxetan.
Cells were treated with indicated doses of 177Lu-lilotomab satetraxetan [600 MBq/mg] for 18 hours, washed and fixated. DNA content (FxCycleFarRed) and DNA damage (anti-P-g-H2AX) were assessed by flow cytometry.
Rødland, G. E., Melhus, K., Dahle, J., Syljuåsen, R., & Patzke, S. (2018). Cell Cycle Kinase Inhibitors Potentiate the Effect of 177lu-Lilotomab Satetraxetan in Treatment of Aggressive Diffuse Large B-Cell Lymphoma Cell Lines.
Figure 3 ADCC induction by (A) obinutuzumab and (B) rituximab in Raji 2R cells relative to untreated Raji cells of corresponding mAb exposure.
Statistical significance by 2-tailed t-test where *** p< 0.001 and ** p< 0.01 (N=3).
Marion M. Malenge, Sebastian Patzke, Anne Hansen Ree,… & and Ada H. V. Repetto-Llamazares. 177Lu-lilotomab satetraxetan has the potential to counteract resistance to rituximab and obinutuzumab in non-Hodgkin’s lymphoma.
Figure 4 177Lu-lilotomab satetraxetan and the increase was dependent on the concentration of 177Lu-lilotomab satetraxetan.
Rituximab binding presented as mean ± SD of median fluorescence intensity (MFI) plotted against escalating concentrations of mAbs at 3 and 6 days in Raji 2R and in Raji cells (N=3).
Marion M. Malenge, Sebastian Patzke, Anne Hansen Ree,… & and Ada H. V. Repetto-Llamazares. 177Lu-lilotomab satetraxetan has the potential to counteract resistance to rituximab and obinutuzumab in non-Hodgkin’s lymphoma.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Afuco™ Anti-CD37 ADCC Recombinant Antibody (Lilotomab), ADCC EnhancedThis product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CD37. Lilotomab is a mouse monoclonal antibody that can be potentially used in the treatment of Non-Hodgkin's lymphoma (NHL).
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-904 | Anti-Human CD37 Recombinant Antibody (Otlertuzumab) | ELISA, IP, FC, FuncS, Neut, IF, ICC | VH - V-kappa - CH2 - CH3 |
There are currently no Customer reviews or questions for TAB-467CQ. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.